Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company, announced a strategic initiative to explore ibogaine-based therapeutics for traumatic brain injury (TBI) and related neuropsychiatric conditions. The company has filed a provisional U.S. patent application covering compositions and methods using ibogaine and related compounds to treat TBI, PTSD, and associated disorders, according to a press release.
The initiative targets underserved conditions such as stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. Silo Pharma’s portfolio includes programs like SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Research is conducted in collaboration with leading universities and laboratories.
Ibogaine, a naturally occurring psychoactive substance, has shown potential in treating addiction and other neurological conditions. By focusing on TBI and PTSD, Silo Pharma aims to address significant unmet medical needs. The company’s approach involves developing novel therapeutics and drug delivery systems to improve treatment outcomes.
For more information, visit the company’s newsroom at https://ibn.fm/SILO. The full press release is available at https://ibn.fm/HdWHG.
This strategic move positions Silo Pharma at the forefront of ibogaine research for TBI, potentially offering new treatment options for patients suffering from these debilitating conditions. The patent filing underscores the company’s commitment to innovative therapies in neuropsychiatry.
